Clinical Trial: NCT03563716
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Genentech, Inc. |
| Information Provided By: | Genentech, Inc. |
| Last Update Posted: | 2026-05-04 |
Study Overview
Brief Summary
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.
Official Title
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Atezolizumab
- Drug: Tiragolumab
- Drug: Placebo
Other Study ID Numbers
- GO40290
- 2018-000280-81
- 2023-508083-30-00
- 2023
- 2018
Start Date (Actual)
2018-08-10
Primary Completion Date (Actual)
2019-06-30
Study Completion Date (Actual)
2025-11-14
Enrollment (Actual)
135
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Genentech, Inc. |
| Information Provided By: | Genentech, Inc. |
| Last Update Posted: | 2026-05-04 |
Study Overview
Brief Summary
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.
Official Title
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Atezolizumab
- Drug: Tiragolumab
- Drug: Placebo
Other Study ID Numbers
- GO40290
- 2018-000280-81
- 2023-508083-30-00
- 2023
- 2018
Start Date (Actual)
2018-08-10
Primary Completion Date (Actual)
2019-06-30
Study Completion Date (Actual)
2025-11-14
Enrollment (Actual)
135
Study Type
Interventional
Phase
Phase 2